China Health Industries Holdings, Inc. engages in the production, marketing, and distribution of medicines, health products, health devices, and cosmetics. The company is headquartered in Harbin, Heilongjiang and currently employs 32 full-time employees. The company went IPO on 2004-12-01. The firm's principal business operations are conducted through its subsidiaries: Harbin Humankind Biology Technology Co., Limited (Humankind) and Heilongjiang Huimeijia Pharmaceutical Co., Ltd (HLJ Huimeijia). The firm owns a GMP-certified plant and production facilities and has the capacity to produce 21 different NMPA-approved medicines, 14 NMPA-approved health supplement products and 8 hemp derivative products in soft capsule, hard capsule, tablet, granule, oral liquid forms. These products address the needs of some key sectors in China, including the feminine, geriatric, and children’s markets.
Follow-Up Questions
Who is the CEO of China Health Industries Holdings Inc?
Mr. Xin Sun is the Chairman of the Board of China Health Industries Holdings Inc, joining the firm since 2007.
What is the price performance of CHHE stock?
The current price of CHHE is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for China Health Industries Holdings Inc?
China Health Industries Holdings Inc belongs to Consumer products industry and the sector is Consumer Staples
What is China Health Industries Holdings Inc market cap?
China Health Industries Holdings Inc's current market cap is $0
